The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene

Martin Hoyle; Gabriel Rogers; Ruth Garside; Tiffany Moxham; Ken Stein

The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy

an evidence review of the submission from Celgene

Martin Hoyle, Gabriel Rogers, Ruth Garside, Tiffany Moxham, Ken Stein

Research output: Book/Report › Commissioned report

Original language	English
Publisher	University of Exeter
Commissioning body	The National Institute for Health and Care Excellence (NICE)
Number of pages	124
Publication status	Published - 2008
Externally published	Yes

Access to Document

Cite this

@book{e56a649c5ade4a1792fd6ece2a3cbcac,

title = "The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene",

author = "Martin Hoyle and Gabriel Rogers and Ruth Garside and Tiffany Moxham and Ken Stein",

year = "2008",

language = "English",

publisher = "University of Exeter",

}

TY - BOOK

T1 - The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy

T2 - an evidence review of the submission from Celgene

AU - Hoyle, Martin

AU - Rogers, Gabriel

AU - Garside, Ruth

AU - Moxham, Tiffany

AU - Stein, Ken

PY - 2008

Y1 - 2008

UR - https://www.nice.org.uk/guidance/ta171

M3 - Commissioned report

BT - The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy

PB - University of Exeter

ER -